These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23440193)

  • 21. Inward Rectifier Potassium Channels (Kir2.x) and Caveolin-3 Domain-Specific Interaction: Implications for Purkinje Cell-Dependent Ventricular Arrhythmias.
    Vaidyanathan R; Van Ert H; Haq KT; Morotti S; Esch S; McCune EC; Grandi E; Eckhardt LL
    Circ Arrhythm Electrophysiol; 2018 Jan; 11(1):e005800. PubMed ID: 29326130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibroblast inward-rectifier potassium current upregulation in profibrillatory atrial remodeling.
    Qi XY; Huang H; Ordog B; Luo X; Naud P; Sun Y; Wu CT; Dawson K; Tadevosyan A; Chen Y; Harada M; Dobrev D; Nattel S
    Circ Res; 2015 Feb; 116(5):836-45. PubMed ID: 25608527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Congenital short QT syndrome: landmarks of the newest arrhythmogenic cardiac channelopathy.
    Pérez Riera AR; Paixão-Almeida A; Barbosa-Barros R; Yanowitz FG; Baranchuk A; Dubner S; Palandri Chagas AC
    Cardiol J; 2013; 20(5):464-71. PubMed ID: 23677719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kir2.1-Na
    Gutiérrez LK; Moreno-Manuel AI; Jalife J
    Heart Rhythm; 2024 May; 21(5):630-646. PubMed ID: 38244712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Function, subcellular localization and assembly of a novel mutation of KCNJ2 in Andersen's syndrome.
    Hosaka Y; Hanawa H; Washizuka T; Chinushi M; Yamashita F; Yoshida T; Komura S; Watanabe H; Aizawa Y
    J Mol Cell Cardiol; 2003 Apr; 35(4):409-15. PubMed ID: 12689820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A heterozygous deletion mutation in the cardiac sodium channel gene SCN5A with loss- and gain-of-function characteristics manifests as isolated conduction disease, without signs of Brugada or long QT syndrome.
    Zumhagen S; Veldkamp MW; Stallmeyer B; Baartscheer A; Eckardt L; Paul M; Remme CA; Bhuiyan ZA; Bezzina CR; Schulze-Bahr E
    PLoS One; 2013; 8(6):e67963. PubMed ID: 23840796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome.
    El Harchi A; McPate MJ; Zhang Yh; Zhang H; Hancox JC
    J Mol Cell Cardiol; 2009 Nov; 47(5):743-7. PubMed ID: 19285083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KCNJ2 mutations in arrhythmia patients referred for LQT testing: a mutation T305A with novel effect on rectification properties.
    Eckhardt LL; Farley AL; Rodriguez E; Ruwaldt K; Hammill D; Tester DJ; Ackerman MJ; Makielski JC
    Heart Rhythm; 2007 Mar; 4(3):323-9. PubMed ID: 17341397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation.
    Luo X; Pan Z; Shan H; Xiao J; Sun X; Wang N; Lin H; Xiao L; Maguy A; Qi XY; Li Y; Gao X; Dong D; Zhang Y; Bai Y; Ai J; Sun L; Lu H; Luo XY; Wang Z; Lu Y; Yang B; Nattel S
    J Clin Invest; 2013 May; 123(5):1939-51. PubMed ID: 23543060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant KCNJ3 and KCNJ5 Potassium Channels as Novel Molecular Targets in Bradyarrhythmias and Atrial Fibrillation.
    Yamada N; Asano Y; Fujita M; Yamazaki S; Inanobe A; Matsuura N; Kobayashi H; Ohno S; Ebana Y; Tsukamoto O; Ishino S; Takuwa A; Kioka H; Yamashita T; Hashimoto N; Zankov DP; Shimizu A; Asakura M; Asanuma H; Kato H; Nishida Y; Miyashita Y; Shinomiya H; Naiki N; Hayashi K; Makiyama T; Ogita H; Miura K; Ueshima H; Komuro I; Yamagishi M; Horie M; Kawakami K; Furukawa T; Koizumi A; Kurachi Y; Sakata Y; Minamino T; Kitakaze M; Takashima S
    Circulation; 2019 Apr; 139(18):2157-2169. PubMed ID: 30764634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel LQT-3 mutation disrupts an inactivation gate complex with distinct rate-dependent phenotypic consequences.
    Bankston JR; Sampson KJ; Kateriya S; Glaaser IW; Malito DL; Chung WK; Kass RS
    Channels (Austin); 2007; 1(4):273-80. PubMed ID: 18708744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The interaction of caveolin 3 protein with the potassium inward rectifier channel Kir2.1: physiology and pathology related to long qt syndrome 9 (LQT9).
    Vaidyanathan R; Vega AL; Song C; Zhou Q; Tan BH; Berger S; Makielski JC; Eckhardt LL
    J Biol Chem; 2013 Jun; 288(24):17472-80. PubMed ID: 23640888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotypes.
    Andelfinger G; Tapper AR; Welch RC; Vanoye CG; George AL; Benson DW
    Am J Hum Genet; 2002 Sep; 71(3):663-8. PubMed ID: 12148092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss-of-function mutations of the K(+) channel gene KCNJ2 constitute a rare cause of long QT syndrome.
    Fodstad H; Swan H; Auberson M; Gautschi I; Loffing J; Schild L; Kontula K
    J Mol Cell Cardiol; 2004 Aug; 37(2):593-602. PubMed ID: 15276028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T75M-KCNJ2 mutation causing Andersen-Tawil syndrome enhances inward rectification by changing Mg2+ sensitivity.
    Tani Y; Miura D; Kurokawa J; Nakamura K; Ouchida M; Shimizu K; Ohe T; Furukawa T
    J Mol Cell Cardiol; 2007 Aug; 43(2):187-96. PubMed ID: 17582433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional and clinical characterization of a mutation in KCNJ2 associated with Andersen-Tawil syndrome.
    Lu CW; Lin JH; Rajawat YS; Jerng H; Rami TG; Sanchez X; DeFreitas G; Carabello B; DeMayo F; Kearney DL; Miller G; Li H; Pfaffinger PJ; Bowles NE; Khoury DS; Towbin JA
    J Med Genet; 2006 Aug; 43(8):653-9. PubMed ID: 16571646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome).
    Tristani-Firouzi M; Jensen JL; Donaldson MR; Sansone V; Meola G; Hahn A; Bendahhou S; Kwiecinski H; Fidzianska A; Plaster N; Fu YH; Ptacek LJ; Tawil R
    J Clin Invest; 2002 Aug; 110(3):381-8. PubMed ID: 12163457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short QT syndrome. Update on a recent entity.
    Maury P; Extramiana F; Sbragia P; Giustetto C; Schimpf R; Duparc A; Wolpert C; Denjoy I; Delay M; Borggrefe M; Gaita F
    Arch Cardiovasc Dis; 2008; 101(11-12):779-86. PubMed ID: 19059573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and functional characterisation of a novel KCNJ2 mutation, Val302del, causing Andersen-Tawil syndrome.
    Ördög B; Hategan L; Kovács M; Seprényi G; Kohajda Z; Nagy I; Hegedűs Z; Környei L; Jost N; Katona M; Szekeres M; Forster T; Papp JG; Varró A; Sepp R
    Can J Physiol Pharmacol; 2015 Jul; 93(7):569-75. PubMed ID: 26103554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of amiodarone on short QT syndrome variant 3 in human ventricles: a simulation study.
    Luo C; Wang K; Zhang H
    Biomed Eng Online; 2017 Jun; 16(1):69. PubMed ID: 28592292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.